Literature DB >> 10438877

Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4(+) T-cell lines determined by the capacity to exploit low concentrations of CCR5.

N Dejucq1, G Simmons, P R Clapham.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) non-syncytium-inducing (NSI) strains predominantly use the chemokine receptor CCR5, while syncytium-inducing (SI) strains use CXCR4. In vitro, SI isolates infect and replicate in a range of CD4(+) CXCR4(+) T-cell lines, whereas NSI isolates usually do not. Here we describe three NSI strains that are able to infect two CD4(+) T-cell lines, Molt4 and SupT1. For one strain, a variant of JRCSF selected in vitro, replication on Molt4 was previously shown to be conferred by a single amino-acid change in the V1 loop (M.T. Boyd et al., J. Virol. 67:3649-3652, 1993). On CD4(+) cell lines expressing different coreceptors, these strains use CCR5 predominantly and do not replicate in CCR5-negative peripheral blood mononuclear cells derived from individuals homozygous for Delta32 CCR5. Furthermore, infection of Molt4 and SupT1 by each of these three strains is potently inhibited by ligands for CCR5, including 2D7, a monoclonal antibody specific for CCR5. CCR5 mRNA was present in both Molt4 and SupT1 by reverse transcription-PCR, although CCR5 protein could not be detected either on the cell surface or in intracellular vesicles. The expanded tropism of the three strains shown here is therefore not due to adaptation to a new coreceptor but due to the capacity to exploit extremely low levels of CCR5 on Molt4 and SupT1 cells. This novel tropism observed for a subset of primary HIV-1 isolates may represent an extended tropism to new CD4(+) cell types in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438877      PMCID: PMC104314     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  84 in total

1.  Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.

Authors:  P Westervelt; H E Gendelman; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

2.  Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.

Authors:  P R Clapham; A McKnight; R A Weiss
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism.

Authors:  N E Sharpless; W A O'Brien; E Verdin; C V Kufta; I S Chen; M Dubois-Dalcq
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.

Authors:  P Westervelt; D B Trowbridge; L G Epstein; B M Blumberg; Y Li; B H Hahn; G M Shaw; R W Price; L Ratner
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

5.  Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages.

Authors:  B Chesebro; J Nishio; S Perryman; A Cann; W O'Brien; I S Chen; K Wehrly
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.

Authors:  S S Hwang; T J Boyle; H K Lyerly; B R Cullen
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

7.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

Authors:  M Tersmette; R E de Goede; B J Al; I N Winkel; R A Gruters; H T Cuypers; H G Huisman; F Miedema
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

8.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

9.  Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates.

Authors:  E M Fenyö; L Morfeldt-Månson; F Chiodi; B Lind; A von Gegerfelt; J Albert; E Olausson; B Asjö
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

10.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

Authors:  Y Koyanagi; S Miles; R T Mitsuyasu; J E Merrill; H V Vinters; I S Chen
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

View more
  22 in total

1.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

2.  Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.

Authors:  Reem Berro; Per Johan Klasse; Danny Lascano; Ayanna Flegler; Kirsten A Nagashima; Rogier W Sanders; Thomas P Sakmar; Thomas J Hope; John P Moore
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

3.  cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor.

Authors:  B Lee; G Leslie; E Soilleux; U O'Doherty; S Baik; E Levroney; K Flummerfelt; W Swiggard; N Coleman; M Malim; R W Doms
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 4.  Bioinformatic analysis of HIV-1 entry and pathogenesis.

Authors:  Benjamas Aiamkitsumrit; Will Dampier; Gregory Antell; Nina Rivera; Julio Martin-Garcia; Vanessa Pirrone; Michael R Nonnemacher; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

5.  Target cell populations of human immunodeficiency virus type 1 in peripheral blood lymphocytes with different chemokine receptors at various stages of disease progression.

Authors:  P Auewarakul; K Sangsiriwut; S Suwanagool; C Wasi
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis.

Authors:  Paul J Peters; W Matthew Sullivan; Maria J Duenas-Decamp; Jayanta Bhattacharya; Chiambah Ankghuambom; Richard Brown; Katherine Luzuriaga; Jeanne Bell; Peter Simmonds; Jonathan Ball; Paul R Clapham
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence.

Authors:  Brian M Taylor; J Scott Foulke; Robin Flinko; Alonso Heredia; Anthony DeVico; Marvin Reitz
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

8.  Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages.

Authors:  Paul J Peters; Jayanta Bhattacharya; Samantha Hibbitts; Matthias T Dittmar; Graham Simmons; Jeanne Bell; Peter Simmonds; Paul R Clapham
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 9.  Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV.

Authors:  Kelechi Chikere; Tom Chou; Paul R Gorry; Benhur Lee
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

10.  Impact of cytokines on replication in the thymus of primary human immunodeficiency virus type 1 isolates from infants.

Authors:  Livia Pedroza-Martins; W John Boscardin; Deborah J Anisman-Posner; Dominique Schols; Yvonne J Bryson; Christel H Uittenbogaart
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.